Drug Profile

AJM 347

Alternative Names: AJM-347

Latest Information Update: 30 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EA Pharma; Ensho Therapeutics
Developer EA Pharma; Eisai Inc
Class Anti-inflammatories; Small molecules
Mechanism of Action Alpha4beta7 integrin antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Inflammatory bowel diseases

Most Recent Events

30 Jun 2025 AJM 347 is in phase I development for Inflammatory bowel disease in European Union (Eisai pipeline, June 2025)
28 May 2025 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases in European Union (PO)
28 Jan 2023 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers, In adults) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com